Time filter

Source Type

Amarillo, TX, United States

Zhang Y.,Laura W Bush Institute For Womens Health | Zhang Y.,University of Technology, Sydney | Leach M.J.,University of Technology, Sydney | Leach M.J.,University of South Australia | And 8 more authors.
Evidence-based Complementary and Alternative Medicine | Year: 2015

We examined the National Health Interview Survey (NHIS) 2012 to explore how US adult consumers of CAM differ by gender in terms of their sociodemographic characteristics, current health conditions, and perceived benefits of CAM. All individuals who completed the adults core interviews (N = 34,525) were included. CAM use, major sociodemographic variables, perceived benefits of using CAM, and top ten reported health conditions for which CAM was used were selected and analyzed by Stata. Findings revealed that 29.6% (n = 10,181) reported having used at least one form of CAM in the previous 12 months. Compared to male CAM users, female CAM users were more likely to have a bachelor degree, to be divorced/separated or widowed, and less likely to earn $75,000 or more. Back pain/problem was the most common problem reported by both male and female CAM users (32.2% and 22.6%, resp.). A higher proportion of female CAM users reported using CAM for perceived benefits such as general wellness or general disease prevention. This paper provides foundation information regarding gender differences in CAM use and is a platform for further in-depth examination into how and why males and females differ in their reasons for CAM use. © 2015 Yan Zhang et al. Source

Arnaboldi F.,University of Milan | Menon A.,University of Milan | Menegola E.,University of Milan | Di Renzo F.,University of Milan | And 10 more authors.
International Reviews of Immunology | Year: 2014

Sperm protein 17 (Sp17) was originally identified in the flagellum of spermatozoa and subsequently included in the subfamily of tumor-associated antigens known as cancer-testes antigens (CTA). Sp17 has been associated with the motility and migratory capacity in tumor cells, representing a link between gene expression patterns in germinal and tumor cells of different histological origins. Here we review the relevance of Sp17 expression in the mouse embryo and cancerous tissues, and present additional data demonstrating Sp17 complex expression pattern in this murine model. The expression of Sp17 in embryonic as well as adult neoplastic cells, but not normal tissues, suggests this protein should be considered an "oncofetal antigen." Further investigations are necessary to elucidate the mechanisms and functional significance of Sp17 aberrant expression in human adult cells and its implication in the pathobiology of cancer. © 2014 Informa Healthcare USA, Inc. Source

Mirandola L.,TTUHSC | Mirandola L.,Laura W Bush Institute For Womens Health | Yu Y.,TTUHSC | Cannon M.J.,University of Arkansas for Medical Sciences | And 13 more authors.
Gynecologic Oncology | Year: 2014

Objective. Ovarian cancer is the most deadly gynecologic malignancy worldwide. Since the pathogenesis of ovarian cancer is incompletely understood, and there are no available screening techniques for early detection, most patients are diagnosed with advanced, incurable disease. In an effort to develop innovative and effective therapies for ovarian cancer, we tested the effectiveness of Galecti-3C in vitro. This is a truncated, dominant negative form of Galectin-3, which is thought to act by blocking endogenous Galectin-3. Methods. We produced a truncated, dominant-negative form of Galectin-3, namely Galetic-3C. Ovarian cancer cell lines and primary cells from ovarian cancer patients were treated with Galectin-3C, and growth, drug sensitivity, and angiogenesis were tested. Result. We show, for the first time, that Galectin-3C significantly reduces the growth, motility, invasion, and angiogenic potential of cultured OC cell lines and primary cells established from OC patients. Conclusions. Our findings indicate that Galectin-3C is a promising new compound for the treatment of ovarian cancer. © 2014 Elsevier Inc. All rights reserved. Source

Cobos C.,Texas Tech University | Figueroa J.A.,Texas Tech University | Figueroa J.A.,Laura W Bush Institute For Womens Health | Figueroa J.A.,Kiromic LLC | And 23 more authors.
International Reviews of Immunology | Year: 2014

Over the past 30 years, human papilloma virus (HPV) has been shown to play a role in the development of various cancers. Most notably, HPV has been linked to malignant progression in neoplasms of the anogenital region. However, high-risk HPV has also been suggested to play a significant role in the development of cancers in other anatomic locations, such as the head and neck, lung, breast and bladder. In 2006, the first vaccine for HPV, Gardasil, was approved for the prevention of subtypes 6, 11, 16 and 18. A few years later, Cevarix was approved for the prevention of subtypes 16 and 18, the HPV subtypes most frequently implicated in malignant progression. Although increased awareness and vaccination could drastically decrease the incidence of HPV-positive cancers, these approaches do not benefit patients who have already contracted HPV and developed cancer as a result. For this reason, researchers need to continue developing treatment modalities, such as targeted immunotherapies, for HPV-positive lesions. Here, we review the potential evidence linking HPV infection with the development of non-anogenital cancers and the potential role of immunotherapy in the prevention and eradication of HPV infection and its oncogenic sequela. © 2014 Informa Healthcare USA, Inc. Source

Zhang Y.,Texas Tech University Health Sciences Center | Zhang Y.,Laura W Bush Institute For Womens Health | Peck K.,Texas Tech University Health Sciences Center | Spalding M.,Texas Tech University Health Sciences Center | And 3 more authors.
Patient Education and Counseling | Year: 2012

Objective: To compare patients' complementary and alternative medicine (CAM) use and physicians' familiarity with certain CAM modalities in the same setting and to assess patient-provider dialogue about patients' CAM use. Methods: An observational survey study with convenience sampling at ambulatory family medicine clinics in two Texas cities. A total of 69 healthcare providers and 468 patients completed the surveys. Patients' surveys assessed use of 27 CAM therapies, perception of CAM use and interaction with providers. Providers' survey assessed perception and attitude toward CAM use. Results: CAM modalities most used by the patients are not those modalities that providers best understood. Of the 330 patients (70%) who responded to the relevant questions about discussing CAM, 44.5% reported never having discussed CAM use with their providers. Binomial logistic regression revealed no link between age, gender or ethnicity for discussing CAM with providers. College-educated patients (adjust OR = 2.8, 95%CI = 1.3-6.0) and US citizens were both about three times more likely to discuss CAM than their counterparts. Conclusion: Lack of knowledge and unfamiliarity with CAM modalities might prevent important patient-provider discussions. Practice implications: Providers should use existing resources and encourage a bilateral dialogue that involves transferring of information and assisting patients in decisions making about CAM use and health care. © 2012 Elsevier Ireland Ltd. Source

Discover hidden collaborations